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1438Long-Term Survival and Late Deaths after
Hematopoietic Cell Transplantation for Primary
Immunodeficiency Diseases and Inborn Errors
of Metabolism
Mary Eapen,1 Kwang Woo Ahn,1 Paul J. Orchard,2 Morton J. Cowan,3 Stella M. Davies,4
Anders Fasth,5 Anna Hassebroek,6 Mouhab Ayas,7 Carmem Bonfim,8 Tracey A. O’Brien,9
Thomas G. Gross,10 Mitchell Horwitz,11 Edwin Horwitz,12 Neena Kapoor,13
Joanne Kurtzberg,11 Navneet Majhail,6 Olle Ringden,14 Paul Szabolcs,15
Paul Veys,16 K. Scott Baker17It is uncertain whether late mortality rates after hematopoietic cell transplantation for severe combined
immunodeficiency (SCID), non-SCID primary immunodeficiency diseases (non-SCID PIDD), and inborn
errors of metabolism (IEM) return to rates observed in the general population, matched for age, sex,
and nationality. We studied patients with SCID (n 5 201), non-SCID PIDD (n 5 405), and IEM (n 5
348) who survived for at least 2 years after transplantation with normal T cell function (SCID) or .95%
donor chimerism (non-SCID PIDD and IEM). Importantly, mortality rate was significantly higher in these
patients compared with the general population for several years after transplantation. The rate decreased
toward the normal rate in patients with SCID and non-SCID PIDD beyond 6 years after transplantation,
but not in patients with IEM. Active chronic graft-versus-host disease at 2 years was associated with
increased risk of late mortality for all diseases (hazard ratio [HR], 1.87; P5 .05). In addition, late mortality
was higher in patients with non-SCID PIDD who received T cell–depleted grafts (HR 4.16; P5 .007) and in
patients with IEM who received unrelated donor grafts (HR, 2.72; P 5 .03) or mismatched related donor
grafts (HR, 3.76; P5 .01). The finding of higher mortality rates in these long-term survivors for many years
after transplantation confirms the need for long-term surveillance.
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nodeficiency and metabolic diseases. Transplantation
remains the standard of care for the majority of chil-
dren with these diseases [2-8].
Patients with SCID have been studied by several
groups, with reports detailing immune reconstitution,
complications, and survival aftermatchedormismatched
related donor transplantation [2,6-8]. However, most
patients in those studies received allografts from
related donors and did not receive pretransplantation
conditioning chemotherapy. Neven et al. [7] reported
a 2-year survival rate of 63% in 149 patients with
SCID who received allografts from related donors (ex-
cept for 2 patients who received allograft from unrelated
donors), only one-half of whom received pretransplanta-
tion conditioning. An additional 8 deaths occurred be-
yond 2 years after poor immune reconstitution,
chronic graft-versus-host disease (GVHD) and related
complications, and endocrine, autoimmune, and inflam-
matory complications [7]. In the study of Railey et al. [8],
in which all patients received an allograft from a related
donor and none received pretransplantation condition-
ing, the timing of transplantation was predictive of out-
come. Transplantation within the first 3.5 months of
life was associated with improved long-term survival,
better nutritional status, and fewer subsequent cellular
infusions to boost engraftment.
Antoine et al. [2] examined long-term survival after
transplantation for SCID and non-SCID PIDD and
reported better long-term survival in recipients of
grafts from HLA-matched sibling donors. More than
90% of the SCID patients and 80% of non-SCID
PIDD patients received their allografts from an
HLA-matched or HLA-mismatched related donor
[2]. A more recent report on long-term outcome after
transplantation for Wiskott-Aldrich syndrome re-
ported a 7-year event-free survival rate of 75% in 96
patients who survived for at least 2 years after trans-
plantation [3]. Two-thirds of patients in that study re-
ceived an allograft from matched or mismatched
donors, and late complications includedGVHD, auto-
immunity, and infections.
Data are sparse on long-term survival after trans-
plantation for IEM and non-SCID PIDD, particularly
after unrelated donor transplantation. Furthermore,
previous reports [2,3,6-8] did not compare the
mortality rate in long-term transplantation survivors
with immune deficiency diseases (SCID or non-
SCID PIDD) and IEM with that in the general popu-
lation. In contrast, late mortality rates in long-term
survivors with severe aplastic anemia and hematologic
malignancies are well documented, and increased rates
are known to persist for years after transplantation
[9-11]. Socie et al. [9] reported no significant differ-
ences in the risk of death compared with the normal
population by the sixth year after transplantation for
severe aplastic anemia and by the ninth year after trans-plantation for acute myelogenous leukemia (AML).
These data stand in contrast to findings of Bhatia
et al. [10], who reported that the risk of late mortality
remained significantly higher in long-term survivors
after transplantation compared with the normal popu-
lation. Similarly, a recent CIBMTR study of patients
with hematologic malignancies and severe aplastic
anemia also confirmed a lower life expectancy in
long-term survivors of transplantation compared to
the general population [11]. Although the study popu-
lation of Socie et al. [9] included fewer than 5% of
unrelated donor transplant recipients, the more recent
reports have included higher proportions of unrelated
donor transplant recipients, possibly explaining the
observed differences between the earlier and later
reports.
We report on late mortality in patients with SCID,
non-SCID PIDD, and IEM who survived at least
2 years after transplantation with normal T cell func-
tion (SCID) and .95% donor chimerism (non-
SCID PIDD and IEM). Including only long-term
survivors allowed us to determine mortality rates in
these patients relative to mortality rates in an age-,
sex-, and nationality-matched general population, as
well as to identify risk factors for late mortality in
patients considered cured of their disease.METHODS
Data Collection
Data were collected by the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR), a voluntary organization of more than
450 transplantation centers worldwide that report con-
secutive transplantations facilitated at their centers to
a statistical center located at the Medical College of
Wisconsin. The CIBMTR database includes detailed
patient, disease, and transplantation characteristics
and their outcome data on approximately 60% of all
transplantations performed. All patients are followed
longitudinally annually, and compliance is monitored
by onsite audits. The Institutional Review Boards of
the Medical College of Wisconsin and the National
Marrow Donor Program approved this study.
Eligibility Criteria
Eligibility for participation was limited to trans-
plantation centers that provided extended follow-up
data on .85% of their surviving patients with SCID,
non-SCID PIDD, and IEM. All patients had to be
alive for longer than 2 years after their transplantation
and demonstrate sustained immunologic recovery or
donor chimerism. Patients with SCID had normal T
cell function, and those with non-SCID PIDD and
IEM had .95% donor chimerism at study entry (ie,
2 years after transplantation). It was expected that
1440 Biol Blood Marrow Transplant 18:1438-1445, 2012M. Eapen et al.deaths due to the early complications of transplanta-
tion would occur before the 2-year period. A total of
954 patients were eligible, and data were reported by
114 transplantation centers. An additional 847 patients
(SCID, n 5 180; non-SCID PIDD, n 5 327; IEM,
n 5 340) underwent transplantation at a participating
center but died within 2 years after transplantation,
had autologous recovery, or failed to attain normal T
cell function within 2 years after transplantation, mak-
ing them ineligible for this analysis.Statistical Methods
The SCID, non-SCID PIDD, and IEM disease
groups were analyzed separately because of differences
in biological features and transplant strategies. Late
deaths were defined as any death occurring beyond 2
years after transplantation. Reported causes of death
were reviewed and categorized. Patients who died
with active chronic GVHD were considered to have
died of this complication. Deaths due to infection in-
cluded only those patients without active GVHD.
The probability of long-term survival was calcu-
lated using the Kaplan-Meier estimator, and 95%
confidence intervals (CIs) were estimated using
Greenwood’s formula [12]. Death from any cause
was considered an event, and surviving patients were
censored at last follow-up. Cox proportional hazards
regression was used to identify risk factors associated
with late deaths for each disease group [13]. Multivar-
iate models were built with the use of stepwise forward
selection, with a P value of #.05 indicating statistical
significance; all variables met the proportional-
hazards assumption. The variables considered in mul-
tivariate analysis were age at transplantation, race, sex,
donor type, graft type, conditioning regimen, use of
antithymocyte globulin, recipient cytomegalovirus
serostatus, GVHD prophylaxis, donor–recipient sex
match, history of grade II-IV GVHD, chronic
GVHD (none versus resolved by 2 years after trans-
plantation versus active chronic at 2 years after trans-
plantation), and year of transplantation (Table 1).
Estimates of relative mortality (ie, excess risk of
mortality) were calculated as described by Andersen
and Vaeth [14], taking into account differences among
the patients in terms of age, sex, and nationality. Rela-
tivemortality is the relative risk of dying at a given time
after transplantation compared with a person of similar
age, sex, and nationality in the general population.
Age-, sex-, and nationality-specific rates for all coun-
tries from which transplantations were reported were
used to calculate the relative mortality. The ratio of
observed to expected cancers and the absolute excess
risk (AER) were estimated. AER is the number of ob-
served cases minus the number of expected cases per
10,000 person-years at risk. The number of person-
years at risk was calculated from the date of transplan-tation to date of diagnosis of solid tumors, date of
death, or date of last contact, whichever occurred first.
Analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC).RESULTS
Patients
The characteristics of the study population are
summarized in Table 1. The cohort included 201 pa-
tients with SCID, 405 with non-SCID PIDD, and
348 with IEM. Transplantations occurred between
1980 and 2003, and the median follow-up of surviving
patients was 83 months (range, 25-283 months). The
median age at last contact was 7 years for patients
with SCID, 9 years for those with non-SCID PIDD,
and 10 years for those with IEM. Age at transplanta-
tion varied depending on the disease for which trans-
plantation was performed; the SCID group was
younger than the non-SCID PIDD and IEM groups.
Transplantation was performed before age 2 years in
97% of the patients with SCID, compared with 65%
of patients with non-SCID PIDD and IEM. In the
SCID group, 70% of patients received an allograft
from an HLA-matched sibling or HLA-mismatched
relative. Transplantation of allografts from an unre-
lated donor was more common in the non-SCID
PIDD and IEM groups, accounting for 55% of the
transplants. Bone marrow was the predominant stem
cell source. All but 27 patients in the SCID group
received pretransplantation conditioning, and 84% re-
ceived a conditioning regimen not including total body
irradiation. The majority of patients in the non-SCID
PIDD (86%) and IEM (90%) groups received a mye-
loablative conditioning regimen. Acute and chronic
GVHD were assessed using standard criteria [15,16].
Grade II-IV acute GVHD developed in 383 of 954 pa-
tients (40%); most patients with GVHD had grade II
or III acute GVHD. Chronic GVHD developed in
209 patients (22%), 119 of whom had active chronic
GVHD at 2 years after transplantation. One hundred
forty-eight of the 209 patients (70%) with chronic
GVHDhad grade II-IV acute GVHDbefore the onset
of chronic GVHD. Chronic GVHD was limited in
118 patients and extensive in 88 patients.Long-Term Survival and Late Mortality
Fourteen patients with SCID (7%), 15 patients
with non-SCID PIDD (4%), and 37 patients with
IEM (11%) died beyond 2 years after transplantation.
The 7-year probabilities of overall survival were 93%
(95% CI, 89%-97%) in the SCID group, 96% (95%
CI, 94%-98%) in the non-SCID PIDD group, and
90% (95% CI, 86%-93%) in the IEM group
(Figure 1). Active chronic GVHD was associated
Table 1. Patient, Disease, and Transplantation Characteristics
Characteristic SCID*
Non-SCID
PIDD† IEM‡
Number of patients 201 405 348
Age at transplantation, years, n (%)
<1 159 (79) 108 (27) 81 (23)
1-2 36 (18) 144 (36) 142 (41)
3-5 3 (1) 79 (19) 54 (15)
6-9 3 (1) 34 (8) 38 (11)
10-15 1 (<1) 29 (7) 16 (5)
>15 0 11 (3) 17 (5)
Male sex, n (%) 118 (59) 296 (73) 201 (58)
Donor type, n (%)
HLA-matched sibling 51 (25) 137 (34) 108 (31)
Mismatched related 93 (46) 50 (12) 41 (12)
Unrelated 57 (28) 218 (54) 199 (57)
Graft type, n (%)
Bone marrow 161 (80) 324 (80) 260 (75)
Peripheral blood progenitor cells 18 (9) 23 (6) 10 (3)
Umbilical cord blood 22 (11) 58 (14) 78 (22)
Conditioning regimen, n (%)
Total body irradiation + cyclophospahmide ± other 5 (2) 42 (11) 85 (25)
Busulfan + cyclophosphamide ± other 92 (46) 333 (82) 252 (72)
Busulfan + other 10 (5) 7 (2) 4 (1)
Busulfan alone 7 (3) 1 (<1) –
Cyclophosphamide + other 21 (10) 10 (2) 2 (<1)
Cyclophosphamide alone 20 (10) 4 (1) 1 (<1)
Fludarabine + other 5 (2) 7 (2) 4 (1)
Antithymocyte globulin 11 ( 5) 1 (<1) –
None 27 (13) – –
GVHD prophylaxis, n (%)
T cell depletion 79 (39) 61 (15) 77 (22)
Cyclosporine + methotrexate 56 (28) 211 (52) 127 (36)
Cyclopsorine ± other agents 55 (27) 114 (28) 128 (36)
Tacrolimus ± other agents 2 (<1) 8 (1) 5 (1)
Methotrexate ± other agents 7 (3) 8 (2) 11 (3)
Other agents 2 (1) 3 (1) 0
Year of transplantation, n (%)
1980-1989 32 (15) 33 (8) 53 (15)
1990-2000 112 (56) 226 (56) 172 (49)
2001-2003 57 (28) 146 (36) 123 (36)
History of grade II-IV acute GVHD, n (%)
None 125 (62) 239 (59) 207 (59)
Yes 76 (38) 166 (41) 141 (41)
Acute GVHD grade, n (%)
0 105 (52) 193 (48) 153 (44)
I 20 (10) 46 (11) 54 (15)
II 46 (23) 85 (21) 75 (22)
III 27 (13) 72 (18) 54 (15)
IV 3 (1) 9 (2) 12 (4)
Chronic GVHD, n (%)
None 163 (81) 310 (77) 272 (78)
Chronic GVHD resolved by 2 years after transplantation 11 (5) 36 (9) 28 (8)
Chronic GVHD active for at least 2 years after transplantation 23 (11) 54 (13) 42 (12)
Chronic GVHD resolved by 2 years, not reported 4 (2) 5 (1) 6 (2)
Age at last contact, years, n (%)
2-5 67 (33) 79 (20) 63 (18)
6-9 61 (30) 143 (35) 101 (29)
10-15 57 (28) 111 (27) 101 (29)
16-20 15 (7) 46 (11) 48 (14)
21-25 1 (<1) 14 (3) 18 (5)
>25 0 13 (3) 17 (5)
Follow-up of survivors, months, median (range)§ 93 (29-244) 75 (25-284) 90 (25-269)
*SCID: ADA deficiency, n5 9 (4%); T2 B26NK activity, n5 76 (38%); T2 B+6NK activity, n5 87 (43%); T+ B26NK activity, n5 20 (10%); T+ B+6
NK activity, n 5 6 (3%); unknown, n 5 3 (2%).
†Non-SCID PIDD:Wiskott-Aldrich syndrome, n5 144 (35%); hemophagocytic lymphohistiocytosis, n5 91 (25%); Langerhan’s cell histiocytosis, n5 12
(3%); Chediak-Higashi syndrome, n5 21 (4%); chronic granulomatous disease, n5 17 (4%); Kostmann agranulocytosis, n5 18 (4%); leukocyte adhesion
deficiency, n 5 15 (4%); X-linked lymphoproliferative disease, n 5 12 (3%); other non-SCID PIDD, n 5 75 (18%).
‡IEM: osteopetrosis, n5 59 (17%); Hurler syndrome, n5 111 (32%); other mucopolysaccharidosis, n5 48 (12%); adrenoleukodystrophy, n5 36 (10%);
metachromatic leukodystrophy, n 5 33 (9%); globoid cell leukodystrophy, n 5 20 (6%); Gaucher’s disease, n 5 13 (4%); other IEM, n 5 33 (10%).
§645 patients were followed for at least 5 years, 440 were followed for at least 7 years, and 235 were followed for at least 10 years.
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Figure 1. The 7-year probability of overall survival for patients who
survived longer than 2 years after transplantation with normal T cell
function (SCID patients) and .95% donor chimerism (non-SCID
PIDD and IEM patients) was 93% for SCID patients, 96% for non-
SCID PIDD patients, and 90% for IEM patients. The 9-year probability
of overall survival was 92% for SCID patients, 96% for non-SCID
PIDD patients, and 88% for IEM patients.
Table 3. Primary Causes of Death in Children Age >6 Years
Cause of Death
SCID
(n 5 4)
Non-SCID
(n 5 3)
IEM
(n 5 10)
Total
(n 5 17)
Chronic GVHD – – 2 2
Infection without GVHD* 2 1 2 5
Organ failure† 1 – 2 3
Brain stem glioma – 1 – 1
Not reported 1 1 4 6
*Infection without GVHD: bacterial infection, n5 3; viral infection, n5
1; no isolate, n 5 1.
†Organ failure: cardiac failure (SCID, n5 1), pulmonary failure (IEM, n5
1), and progressive neurologic deterioration (Gaucher’s disease, n5 1).
1442 Biol Blood Marrow Transplant 18:1438-1445, 2012M. Eapen et al.with a higher risk of mortality in all patients (HR, 1.87;
95% CI, 0.99-3.53; P5 .05). Other risk factors associ-
ated with late mortality differed by disease type. Late
mortality was greater in recipients of T cell–depleted
allografts (HR, 4.16; 95% CI, 1.49-11.76; P 5 .007)
in patients with non-SCID PIDD and for patients
with IEM who received allografts from unrelated do-
nors (HR, 2.72; 95% CI, 1.11-6.71; P 5 .03) and
mismatched related donors (HR, 3.76; 95% CI, 1.34-
10.52; P 5 .01) compared with HLA-matched sibling
donors. Late mortality risk did not differ between
patients with B- SCID and those with B1 SCID (HR,
1.60; 95%CI, 0.31-8.33; P5 .57). The primary causes
of late mortality are listed in Tables 2 and 3. There
were 66 late deaths, including 49 deaths occurring
2-6 years after transplantation and 17 deaths after
6 years. The most common causes of late death were
chronic GVHD, infections not associated with
chronic GVHD, and organ failure.
Malignancy accounted for 5% of the late deaths
(n5 3). Eightmalignancies occurred 2 years after trans-
plantation, excluding 2 patients with nonmelanoma
skin cancer and2patientswith posttransplantation lym-Table 2. Primary Causes of Death in Children Age 2-6 Years
Cause of Death
SCID
(n 5 10)
Non-SCID
(n 5 12)
IEM
(n 5 27)
Total
(n 5 49)
Chronic GVHD 2 5 7 14
Infection without GVHD* 3 2 6 11
Organ failure† 3 – 10 13
PTLD-EBV positive 1 1 – 2
AML – 2 – 2
Graft failure – 1 – 1
Seizure – – 1 1
Accidental death – 1 1 2
Acute abdomen – – 1 1
Not reported 1 – 1 2
*Infection without GVHD: bacterial, n5 8; viral, n5 1; no isolate, n5 2.
†Organ failure: multiorgan failure (IEM, n 5 1), cardiac (SCID, n 5 2;
IEM, n 5 3), and pulmonary (SCID, n 5 1; IEM, n 5 5).phoproliferative disorder positive for Epstein-Barr
virus (PTLD-EBV), which occurred at 36 months and
39 months after transplantation, respectively. Two pa-
tients developed AML, 1 patient had myelodysplastic
syndrome (MDS), and 5 patients had solid tumors (1
each with Hodgkin’s lymphoma, kidney tumor, brain
stem glioma, melanoma, and mucoepidermoid carci-
noma) (Table 4). The median time to development of
leukemia, MDS, and solid tumors was 72 months
(range, 45-240 months) in patients with non-SCID
PIDD. AML and MDS developed in patients who had
received total body irradiation (.1000 cGy dose). All
malignancies but 1 occurred in patients age\10 years
at transplantation.
The relativemortality rate for each disease category
was calculated to compare mortality in the transplant
recipients and an age-, sex- and nationality-matched
general population (Table 5). The risk of mortality at
2-6 years after transplantation exceeded that for the
general population in all patients. Beyond 6 years, the
mortality risk was not different from that for the gen-
eral population in patients with SCID and non-SCID
PIDD; however, in patients with IEM, the risk re-
mained higher than that for the general population,
even beyond 6 years after transplantation.DISCUSSION
Patients are at high risk of dying from a transplan-
tation-related complication or recurrence of primary
disease within the first 2 years after transplantation.
Thereafter, the risk is substantially lower, with the sur-
vival curve reaching a plateau. However, the risk for
late mortality persists for several years after transplan-
tation and is linked to several factors, including
pretransplantation treatment, transplantation condi-
tioning regimen, chronic GVHD, infections, and
autoimmunity [2-11]. We examined late mortality in
a large group of patients with SCID, non-SCID
PIDD, and IEMwho survived longer than 2 years after
transplantation with normal T cell function (SCID)
and .95% donor chimerism (non-SCID PIDD and
IEM). There are important differences in the patient
characteristics between our study population and the
Table 4. Ratio of Observed to Expected Cases and Absolute Excess Risk of New Malignancy Occurring 2 Years after Trans-
plantation
Primary Disease New Malignancy Observed Expected Observed:Expected (95% CI) P Value AER*
Chronic granulomatous disease Melanoma of skin 1 0.0027 370.33 (9.37-2063) .005 1.40
Wiskott-Aldrich syndrome Kidney 1 0.0656 15.23 (0.39-84.85) .127 1.31
Hemophagocytic lymphohistiocytosis Brain stem glioma 1 0.0212 46.98 (1.19-262) .042 1.37
Hemophagocytic lymphohistiocytosis Hodgkin’s lymphoma 1 0.0727 13.75 (0.35-76.63) .140 1.30
Wiskott-Aldrich syndrome AML 2 0.0533 37.55 (4.55-135.66) .003 2.72
Chediak-Higashi syndrome MDS 1 0.0516 19.38 (0.49-108) .101 1.33
Langerhan cell histiocytosis Mucoepidermoid cancer 1 0.2043 4.89 (0.12-27.27) .369 1.11
*Absolute excess risk; number of observed cases minus number of expected cases per 10,000 person-years at risk.
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(1) patients were alive longer than 2 years after
transplantation, with sustained immunologic recovery
or donor chimerism; (2) the majority of patients with
SCID received chemotherapy for pretransplantation
conditioning, and one-third received an allograft
from an unrelated donor; and (3) more than one-half
of all patients with non-SCID PIDD and IEM re-
ceived an allograft from an unrelated donors.
The majority of the patients in the current analysis
were long-term survivors, with 7-year posttransplanta-
tion survival rates of 93% for the SCID group, 96% for
the non-SCID PIDD group, and 90% for the IEM
group.Overall, 7%of surviving patients died of a trans-
plantation-related complication more than 2 years
after the procedure, confirming that the risk of late
mortality after transplantation is not negligible. High
relative mortality in transplant recipients compared
with an age-, sex-, and nationality-matched general
population was observed in all patients for as long as
6 years after transplantation. Excess mortality beyond
6 years was seen only in the IEM group. This high
mortality risk in the IEM group may reflect failure of
the transplantation procedure to prevent progression
of end-organ damage or to fully correct organ dysfunc-
tion that might have occurred as a consequence of
the disease process before or shortly after transplanta-
tion [4].
Active chronic GVHD was associated with higher
mortality in all 3 disease groups. Previous studies
also identified active chronic GVHD as a significant
contributor to long-termmorbidity andmortality after
transplantation formalignant diseases, aplastic anemia,
SCID, andWiskott-Aldrich syndrome [3,6,7,9-11,17].
In our analysis, the risk of late mortality was notTable 5. Estimated Excess Deaths per 1000 Compared with
an Age-, Sex-, and Nationality-Matched General Population
Excess Deaths per 1000 (95% CI)
SCID Non-SCID IEM
2-6 years after HSCT 54 (28-79)* 38 (25-51)* 90 (77-103)*
6-10 years after HSCT 25 (22-51) 16 (26-39) 33 (15-50)*
*Significant difference in excess deaths compared with an age- and sex-
matched general population.associated with transplant donor source in the SCID
and non-SCID PIDD groups, in contrast to a previous
report [2]. However, donor source was associated with
late mortality in the patients with IEM; the risk of
mortality was greater after mismatched related and
unrelated donor transplantation compared with
HLA-matched sibling transplantation. Changes in
transplantation strategies, including donor selection
(donor–recipient HLA matching at the allele level at
HLA-A, -B, -C, DRB1) and improvements in support-
ive care, have resulted in fewer early deaths from
transplantation-related complications and may result
in comparable improvement in late outcomes after al-
ternative donor transplantations in the current era.
The current analysis is limited to those who survived
for 2 years or longer after transplantation.We hypoth-
esize donor source might not be associated with sur-
vival beyond 2 years after transplantation as the
majority of complications attributed to donor source
would have occurred earlier post-transplant.
Consistent with previous reports, the most fre-
quent causes of death in our series were chronic
GVHD, infection without chronic GVHD, and organ
failure [3,7,9-11]. In patients with chronic GVHD,
death may occur as a direct complication of GVHD,
such as bronchiolitis obliterans, or as a consequence
of the immunodeficiency associated with chronic
GVHD, which increases the susceptibility to infection
and death [17,18]. Information on the burden of
morbidity in patients with chronic GVHD is not
available [19]; this is a limitation when using data col-
lected by an observational registry.
Death from infection in the absence of chronic
GVHD was also frequent in our series. Approximately
75% of late infections were bacterial, indicating persis-
tent immunodeficiency after transplantation [20]. Or-
gan failure was common, especially in the SCID and
IEM groups. Cardiopulmonary failure was the most
frequently cited cause of organ failure. Death from
organ failure might be related to the transplantation
procedure, organ toxicity from radiation or chemo-
therapeutic agents used for pretransplantation condi-
tioning, or the underlying disease. Patients with
immunodeficiency are susceptible to bronchopulmo-
nary infection before transplantation, and patients
1444 Biol Blood Marrow Transplant 18:1438-1445, 2012M. Eapen et al.with IEM may have cardiopulmonary end-organ
dysfunction at the time of transplantation. The major-
ity (90%) of our patients with IEM received a myeloa-
blative conditioning regimen, and it remains to be
seen whether recent strategies aimed at reducing
transplantation-related complications, such as substi-
tution of treosulfan for busulfan [21], reduces the
risk of fatal organ toxicity in long-term survivors. Or-
gan failure also can be autoimmune-mediated, and au-
toimmunity without chronic GVHD has been
documented in long-term survivors with SCID and
non-SCID PIDD [3,6,7].
Malignancy excluding PTLD-EBV accounted for
5%of the late deaths in our series;malignancy occurred
only in patients with non-SCID PIDD. The increased
risk of malignancy compared with the general popula-
tion matched for age, sex, and nationality was confined
to melanomas, brain stem gliomas, and AML. Our
study population is relatively small, and the cancers
noted to occur in excess limited by 1 or 2 events com-
pared to an age, sex-matched general population. The
occurrence of solid tumors after allogeneic transplanta-
tion is well documented, and the risk increases
with longer follow-up [22-24]. Posttransplantation
malignancy has been associated with altered immune
system/function after transplantation, very young age
at transplantation, irradiation-containing pretrans-
plantation conditioning regimens, and transplantation
of T cell–depleted allografts, all of which are known
risk factors [22-24].
Transplantation strategies have evolved, and in
recent years, more aggressive measures have been in-
stituted with respect to defining suitably matched re-
lated or unrelated donors, GVHD prevention, and
infection surveillance and treatment. Thus, several of
the late complications that resulted in death in our se-
ries may no longer be as relevant for patients undergo-
ing transplantation today. Only 25% of our surviving
patients had more than 10 years of follow-up, and
complications occurring beyond this period are under-
reported. Curtis et al. [22] reported a sharp increase in
new solid malignancies at 15 years after bone marrow
transplantation for hematologic malignancies, and
Baker et al. [25] reported increases in diabetes, hyper-
tension, and cardiovascular events after transplanta-
tion in very long-term survivors.
Although the probability of long-term survival after
transplantation for SCID, non-SCID PIDD, and IEM
is high, the risk ofmortality is substantially greater than
that expected for a normal general population for sev-
eral years after transplantation. Allogeneic transplanta-
tion is unlikely to reverse any end-organ damage
occurring before transplantation, and for some of the
IEM diseases, progressive end-organ damage persists
despite adequate engraftment. Furthermore, this treat-
ment might not fully correct the immunologic or met-
abolic defect, resulting in continued interplay betweeninflammatory process and poorly regulated cellular re-
pair. Consequently, late mortality could be attributed
to the primary disease, as well as to the transplantation
procedure. We recommend life long surveillance to
prevent and treat life-threatening late complications
and better define the long-term risks of transplantation
for SCID, non-SCID PIDD, and IEM. This surveil-
lance should include assessment for chronic GVHD,
pulmonary function, and cardiovascular risk (including
echocardiography and lipid profile), diabetes, obesity,
and renal function, in addition to other recommended
tests [26]. Others have reported that survivors experi-
ence considerable difficulty in holding jobs and obtain-
ing health insurance [10], which likely will hinder life
long surveillance of survivors of transplantation in
countries without national health insurance.ACKNOWLEDGMENTS
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